![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
KD Wild, J McCormick, EJ Bilsky, T Vanderah, RW McNutt, KJ Chang and F Porreca
Department of Pharmacology, University of Arizona Health Sciences Center, Tucson.
This study explored the antinociceptive properties of (+-)-4-[(alpha- R*)-alpha-[(2S*,5R*)-4-allyl-2,5-dimethyl-1-piperazinol]-3-hydroxy benzyl] - N,N-diethyl-benzamide dihydrochloride (BW373U86) a nonpeptidic compound proposed to be a delta opioid agonist, using three models of nociception and four routes of administration in mice. BW373U86 produced dose- and time-dependent, naloxone-sensitive antinociception in both the tail-flick and tail-pinch assays when given intrathecally (i.t.). However, at doses up to 187 nmol/mouse, i.c.v. BW373U86 was inactive in the tail-flick or tail-pinch assays. Additionally, at doses up to 187 mumol/kg, BW373U86 was not active after i.p. or p.o. administration in these endpoints. Further, in the tail-flick test, i.c.v. BW373U86 did not antagonize the antinociceptive effects of i.c.v. [D-Pen2,D-Pen5]enkephalin or [D-Ala2,Glu4]deltorphin, but partially antagonized the effects of i.c.v. morphine. In the acetic- acid abdominal constriction assay, BW373U86 produced dose-dependent antinociceptive effects when given by the i.p., i.c.v. or i.t., but not by the p.o., routes. Intrathecal BW373U86 was 663-fold more potent in the abdominal constriction assay than when given by the same route in the tail-flick test. The effects of an A70 dose of i.p. or i.c.v. BW373U86 in the abdominal constriction assay were partially antagonized by i.c.v. naloxone, but not by i.c.v. N,N-diallyl-Tyr-Aib- Aib-Phe-Leu- OH, where Aib is alpha-aminoisobutyric acid (ICI-174,864) or naltrindole. In contrast, i.t. naloxone, ICI-174,864 or naltrindole antagonized the antinociceptive effect of i.p. or i.t. BW373U86 in the abdominal constriction assay.(ABSTRACT TRUNCATED AT 250 WORDS)
This article has been cited by other articles:
|
|
 |
|
  E. E. Codd, J. R. Carson, R. W. Colburn, S. L. Dax, D. Desai-Krieger, R. P. Martinez, L. A. McKown, L. A. Neilson, P. M. Pitis, P. L. Stahle, et al. The Novel, Orally Active, Delta Opioid RWJ-394674 Is Biotransformed to the Potent Mu Opioid RWJ-413216 J. Pharmacol. Exp. Ther., September 1, 2006; 318(3): 1273 - 1279. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. M. Jutkiewicz, N. P. Walker, J. E. Folk, K. C. Rice, P. S. Portoghese, J. H. Woods, and J. R. Traynor Comparison of Peptidic and Nonpeptidic {delta}-Opioid Agonists on Guanosine 5'-O-(3-[35S]thio)triphosphate ([35S]GTP{gamma}S) Binding in Brain Slices from Sprague-Dawley Rats J. Pharmacol. Exp. Ther., March 1, 2005; 312(3): 1314 - 1320. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. J. Gengo, H. O. Pettit, S. J. O'Neill, K. Wei, R. McNutt, M. J. Bishop, and K.-J. Chang DPI-3290 [(+)-3-(({alpha}-R)-{alpha}-((2S,5R)-4-Allyl-2,5-dimethyl-1-piperazinyl)-3-hydroxybenzyl)-N-(3-fluorophenyl)-N-methylbenzamide]. I. A Mixed Opioid Agonist with Potent Antinociceptive Activity J. Pharmacol. Exp. Ther., December 1, 2003; 307(3): 1221 - 1226. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. C. Broom, J. F. Nitsche, J. E. Pintar, K. C. Rice, J. H. Woods, and J. R. Traynor Comparison of Receptor Mechanisms and Efficacy Requirements for delta -Agonist-Induced Convulsive Activity and Antinociception in Mice J. Pharmacol. Exp. Ther., November 1, 2002; 303(2): 723 - 729. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Kodani, Y.-T. Xuan, K. Shinmura, H. Takano, X.-L. Tang, and R. Bolli delta -Opioid receptor-induced late preconditioning is mediated by cyclooxygenase-2 in conscious rabbits Am J Physiol Heart Circ Physiol, November 1, 2002; 283(5): H1943 - H1957. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. R. Brandt, M. S. Furness, N. K. Mello, K. C. Rice, and S. S. Negus Antinociceptive Effects of {delta}-Opioid Agonists in Rhesus Monkeys: Effects on Chemically Induced Thermal Hypersensitivity J. Pharmacol. Exp. Ther., March 1, 2001; 296(3): 939 - 946. [Abstract] [Full Text]
|
|
|
|
|
|
D. C. Broom, L. Guo, A. Coop, S. M. Husbands, J. W. Lewis, J. H. Woods, and J. R. Traynor BU48: A Novel Buprenorphine Analog That Exhibits delta -Opioid-Mediated Convulsions but Not delta -Opioid-Mediated Antinociception in Mice J. Pharmacol. Exp. Ther., September 1, 2000; 294(3): 1195 - 1200. [Abstract] [Full Text]
|
|
|
|
|
|
Y.-F. Su, R. W. McNutt, and K.-J. Chang Delta-Opioid Ligands Reverse Alfentanil-Induced Respiratory Depression but Not Antinociception J. Pharmacol. Exp. Ther., December 1, 1998; 287(3): 815 - 823. [Abstract] [Full Text]
|
|
|
|
|
|
S. F. Sezen, V. A. Kenigs, and D. R. Kapusta Renal Excretory Responses Produced by the Delta Opioid Agonist, BW373U86, in Conscious Rats J. Pharmacol. Exp. Ther., October 1, 1998; 287(1): 238 - 245. [Abstract] [Full Text]
|
|
|
|
|
|
S. S. Negus, M. B. Gatch, N. K. Mello, X. Zhang, and K. Rice Behavioral Effects of the Delta-Selective Opioid Agonist SNC80 and Related Compounds in Rhesus Monkeys J. Pharmacol. Exp. Ther., July 1, 1998; 286(1): 362 - 375. [Abstract] [Full Text]
|
|
|
|
|
|
S. J. O'Neill, M. A. Collins, H. O. Pettit, R. W. McNutt, and K.-J. Chang Antagonistic Modulation Between the Delta Opioid Agonist BW373U86 and the Mu Opioid Agonist Fentanyl in Mice J. Pharmacol. Exp. Ther., July 1, 1997; 282(1): 271 - 277. [Abstract] [Full Text]
|
|
|
|
|
|
M. J. Hepburn, P. J. Little, J. Gingras, and C. M. Kuhn J. Pharmacol. Exp. Ther., June 1, 1997; 281(3): 1350 - 1356. [Abstract] [Full Text]
|
|
 |
 |
 |
|
 |
 |
 |
